Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.5K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.5K
Seizures: Classification01:13

Seizures: Classification

1.8K
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
1.8K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.5K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.5K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.1K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.1K
Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders01:27

Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders

2.2K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
2.2K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

855
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
855

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Information needs of patients considering epilepsy surgery: A scoping review.

Epilepsia·2026
Same author

Comparison of Consumer Smartwatch and Research-Grade Accelerometer-Derived Step Counts in Amyotrophic Lateral Sclerosis.

Muscle & nerve·2026
Same author

Low diagnostic yield of presurgical genetic testing in adult patients with epilepsy.

Epilepsia·2026
Same author

A translational multimodal machine-learning prototype predicting valproate response in epilepsy treatment.

Epilepsia·2026
Same author

7 Tesla MRI links poorer cognitive function to higher perivascular space burden in neuroPASC.

medRxiv : the preprint server for health sciences·2026
Same author

Epilepsy in emerging adulthood: Clinical, psychosocial, and surgical challenges.

Epilepsia·2026

Related Experiment Video

Updated: Feb 27, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.7K

Psychiatric comorbidities in epilepsy.

Colin B Josephson1, Nathalie Jetté1

  • 1a Department of Clinical Neurosciences , Hotchkiss Brain Institute and O'Brien Institute for Public Health, Cumming School of Medicine, University of Calgary , Calgary , AB , Canada.

International Review of Psychiatry (Abingdon, England)
|July 7, 2017
PubMed
Summary

Psychiatric comorbidities like depression and anxiety are 2-3 times more common in epilepsy patients. This review covers their prevalence, causes, screening, and treatment in epilepsy.

Keywords:
Mental healthanxietydepressionepidemiologypsychosis

More Related Videos

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.4K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

21.2K

Related Experiment Videos

Last Updated: Feb 27, 2026

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
09:57

Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization

Published on: September 20, 2024

3.7K
Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale
07:35

Behavioral Characterization of Pentylenetetrazole-induced Seizures: Moving Beyond the Racine Scale

Published on: July 8, 2025

1.4K
Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy
10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

21.2K

Area of Science:

  • Neurology
  • Psychiatry
  • Epilepsy Research

Background:

  • Epilepsy frequently co-occurs with psychiatric disorders, including mood, anxiety, and psychotic conditions.
  • These comorbidities manifest at rates significantly higher (2-3 fold or more) than in the general population.
  • Understanding these co-occurring conditions is crucial for comprehensive patient care.

Purpose of the Study:

  • To review the epidemiology of psychiatric disorders in epilepsy.
  • To explore hypotheses on the pathogenesis of these comorbidities.
  • To discuss treatment implications and screening strategies for psychiatric conditions in epilepsy patients.

Main Methods:

  • Literature review and synthesis of existing research on psychiatric comorbidities in epilepsy.
  • Discussion of epidemiological data, etiological hypotheses, and clinical management.
  • Focus on major depressive disorder, anxiety disorders, psychotic disorders, and suicide risk.

Main Results:

  • Psychiatric disorders are highly prevalent in epilepsy populations.
  • Several hypotheses exist regarding the underlying mechanisms linking epilepsy and psychiatric conditions.
  • Screening and appropriate treatment are essential for managing these comorbidities.

Conclusions:

  • Psychiatric comorbidities are a significant concern in epilepsy management.
  • Further research is needed to fully elucidate the pathogenesis and optimize treatment strategies.
  • Integrated care approaches are vital for improving outcomes in individuals with epilepsy and co-existing psychiatric disorders.